m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05373
 [1]
Non-coding RNA MIAT YTHDF2  lncRNA       miRNA   circRNA Direct Enhancement m6A modification CPT1A CPT1A Ythdf2 : m6A sites
m6A Modification:
m6A Regulator YTH domain-containing family protein 2 (YTHDF2) READER
 Regulator Info 
m6A Target Carnitine O-palmitoyltransferase 1, liver isoform (CPT1A)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Myocardial infarction associated transcript (MIAT) LncRNA View Details
Regulated Target YTH domain-containing family protein 2 (YTHDF2) View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs directly impacts m6A modification through modulating the expression level of m6A regulator
Crosstalk Summary YTHDF2 function was a downstream of MIAT in cardiac hypertrophy. Finally, we found that MIAT was a necessary regulator of cardiac hypertrophy due to its regulation of the Ythdf2/PPARalpha/Carnitine O-palmitoyltransferase 1, liver isoform (CPT1A) axis. This study indicated a new hypertrophic signaling pathway: MIAT/Ythdf2/PPARalpha/CPT-1a. The results provided a new understanding of the MIAT and m6A RNA methylation reading protein, Ythdf2, function and mechanism in cardiac hypertrophy and highlighted the potential therapeutic benefits in the heart.
Responsed Disease Heart failure ICD-11: BD1Z
 Disease Info 
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
BD1Z: Heart failure 25 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Digitoxin Approved [2]
Synonyms
Acedoxin; Asthenthilo; Cardidigin; Cardigin; Cardiolanata; Carditalin; Carditoxin; Coramedan; Cristapurat; Crystodigin; Digicor; Digilanid; Digilong; Digimed; Digimerck; Digipural; Digisidin; Digitoksim; Digitoksin; Digitophyllin; Digitossina; Digitoxina; Digitoxine; Digitoxinum; Digitoxoside; Digitoxosidum; Digitrin; Ditaven; Glucodigin; Lanatoxin; Lanostabil; Monodigitoxoside; Myodigin; Natigal; Pandigal; Panlanat; Purodigin; Purpurid; Tardigal; Unidigin; Crystalline digitalin; Digitaline cristallisee; Digitaline nativelle; Digitalinum verum; Digitossina [DCIT]; Digitoxigenin tridigitoxoside; LT00244784; Crystodigin (TN); De-Tone; Digitalin, crystalline; Digitaline (TN); Digitoxigenin-tridigitoxosid; Digitoxigenin-tridigitoxosid [German]; Digitoxina [INN-Spanish]; Digitoxine [INN-French]; Digitoxinum [INN-Latin]; Mono-digitoxid; Mono-digitoxid [German]; Mono-glycocard; Purodigin, crystalline; Tri-digitoxoside; Tri-digitoxoside [German]; Digitoxin [INN:BAN:JAN]; Digitoxin (JP15/USP/INN); Inhibits Na+/K+ ATPase; 5.beta.-Card-20(22)-enolide, 3.beta.,14-dihydroxy-, 3-[tris-(digitoxoside)]
    Click to Show/Hide
External Link
CID: 441207
TTD: D0M3QP
DrugBank: DB01396
 Compound Name Celacade Approved [3]
Synonyms
Celacade (TN)
    Click to Show/Hide
External Link
TTD: D0K5CX
 Compound Name Deslanoside Approved [4]
Synonyms
Ceglunat; Desace; Deslanosido; Deslanosidum; Glucodigoxin; Lekozid; Sediranido; Deacetyllanatoside C; DesacetylLanatoside; Desacetyldigilanide C; Desacetyllanatoside C; Deslanatoside C; Deslanosidum C; Lanatosid C; Cedilanid-D; Desacetyl-Lanatoside C; Deslanosido [INN-Spanish]; Deslanosidum [INN-Latin]; Cedilanid-d (TN); Deslanoside (JP15/USP/INN); Deslanoside [USAN:BAN:INN:JAN]; (3beta,5beta,12beta)-3-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; 3-[(O-beta-D-glucopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3beta,5beta,12beta-card-20(22)-enolide; 3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy-12beta,14-dihydroxy-5beta,14beta-card-20(22)-enolid; 3beta-(O-beta-D-Glucopyranosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-O-beta-D-digitoxosyl-(1-4)-beta-D-digitoxosyloxy=12beta.14=dihydroxy-5beta,14beta-card-20(22)-enolid; 3beta-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12beta,14-dihydroxy-5beta-card-20(22)-enolide
    Click to Show/Hide
External Link
CID: 28620
TTD: D07TGN
DrugBank: DB01078
 Compound Name Digoxin Approved [5]
Synonyms
20830-75-5; 12beta-Hydroxydigitoxin; Digoxine; Lanoxin; Lanoxicaps; Digossina; Digoxina; Digoxinum; Digosin; Lanicor; Digacin; Dilanacin; CHEBI:4551; MLS000069819; Lanacordin; Cardiogoxin; Eudigox; Davoxin; SMR000059217; Rougoxin; Mapluxin; Lenoxin; Lanacrist; Dynamos; Vanoxin; Neo-Lanicor; Lanoxin PG; Digoxin Pediatric; Digoxin Nativelle; SK-Digoxin; UNII-73K4184T59; Homolle's digitalin; Hemigoxine Nativelle; MFCD00003674; Digitek (TN); Lanoxicaps (TN); Lanoxin (TN); Digoxin (JP15/USP); (3beta,5beta,12beta)-3-{[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide; 4-[(1S,2S,5S,7R,10R,11S,14R,15S,16R)-5-{[(2R,4S,5S,6R)-5-{[(2S,4S,5S,6R)-5-{[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-11,16-dihydroxy-2,15-dimethyltetracyclo[8700^{2,7}; [3H]digoxin
    Click to Show/Hide
External Link
CID: 2724385
TTD: D02OZE
DrugBank: DB00390
 Compound Name Recombinant human neuregulin-1 beta Phase 3 [6]
External Link
TTD: D0O5KY
 Compound Name Satavaptan Phase 3 [7]
External Link
CID: 158348
TTD: D0L9NX
DrugBank: DB14923
 Compound Name Neucardin Phase 2 [8]
Synonyms
Human neuregulin-1 recombinant peptide fragment (injectable, heart failure/cardiomyopathy), Zensun; RhNRG-1 (injectable, heartfailure/cardiomyopathy), Zensun
    Click to Show/Hide
External Link
TTD: D00ZPR
 Compound Name Subcutaneous furosemide Application submitted [8]
External Link
TTD: D0MM5P
 Compound Name C-Cure Phase 2/3 [9]
Synonyms
Autologous stem cell/cardiopoietic cell therapy (C-Cath, chronic heart failure), Mayo/Cardio3
    Click to Show/Hide
External Link
TTD: D09VKP
 Compound Name RT-400 Phase 2 [8]
Synonyms
JNJ-39588146
    Click to Show/Hide
External Link
TTD: DYSA16
 Compound Name Cinaciguat Phase 2 [10]
Synonyms
329773-35-5; BAY 58-2667; BAY582667; UNII-59K0Y58UAD; BAY-58-2667; 59K0Y58UAD; 4-({(4-carboxybutyl)[2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl]amino}methyl)benzoic acid; Cinaciguat [INN:JAN]; cinaciguatum; Z90; Cinaciguat (JAN/INN); SCHEMBL249267; GTPL5168; CHEMBL1236936; QCR-279; Cinaciguat (BAY 58-2667); MolPort-039-139-611; CHEBI:142433; ZINC3934935; BCP07942; 3550AH; AKOS026750293; AN-1845; CS-1169; HY-14181; KB-40005; AB0095741; D07577; W-5794
    Click to Show/Hide
External Link
CID: 9808022
TTD: D0ZT0G
 Compound Name Neladenoson bialanate Phase 2 [8]
Synonyms
UNII-IV690462VZ; IV690462VZ; 1239309-58-0; Neladenoson dalanate; Neladenoson dalanate [INN]; Neladenoson bialanate [INN]; SCHEMBL7904070; AKOS032946515; DB13138; L-Alanine, L-alanyl-, 2-(4-(2-(((2-(4-chlorophenyl)-4-thiazolyl)methyl)thio)-3,5-dicyano-6-(1-pyrrolidinyl)-4-pyridinyl)phenoxy)ethyl ester; 2-(4-(2-(((2-(4-Chlorophenyl)-1,3-thiazol-4-yl)methyl)sulfanyl)-3,5-dicyano-6-(pyrrolidin-1-yl)pyridin-4-yl)phenoxy)ethyl L-alanyl-L-alaninate
    Click to Show/Hide
External Link
CID: 56848985
TTD: D0UD1Y
DrugBank: DB13138
 Compound Name CLR325 Phase 2 [8]
External Link
TTD: D0R1UE
 Compound Name Mesenchymal stem cell therapy Phase 2 [8]
External Link
TTD: D0H7TS
 Compound Name CLP-1001 Phase 2 [11]
Synonyms
Cross-linked polyelectrolyte polymer (renal disease), Sorbent Therapeutics
    Click to Show/Hide
External Link
TTD: D0D1ZS
 Compound Name BMS-986231 Phase 2 [12]
Synonyms
N-Hydroxy-5-methylfuran-2-sulfonamide; Cimlanod; Cimlanod [USAN]; UNII-2US4FK1EPV; 2US4FK1EPV; SCHEMBL15878610; LIXKIXWSKOENAB-UHFFFAOYSA-N; ZINC145617689; 2-Furansulfonamide, N-hydroxy-5-methyl-; 1620330-72-4
    Click to Show/Hide
External Link
CID: 76685198
TTD: D0AG8L
DrugBank: DB14983
 Compound Name CXL-1020 Phase 2 [13]
External Link
CID: 52939580
TTD: D0AD4D
DrugBank: DB15326
 Compound Name SLV 306 Phase 2 [14]
Synonyms
Daglutril; SLV-306; SLV306; UNII-KKV299446X; 182821-27-8; KKV299446X; ((3S)-3-{1-((2R)-2-Ethoxycarbonyl-4-phenylbutyl)cyclopentanecarboxamido}-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)acetic acid; Daglutril [INN]; 2-[(3S)-3-[[1-[(2R)-2-ethoxycarbonyl-4-phenylbutyl]cyclopentanecarbonyl]amino]-2-oxo-4,5-dihydro-3H-1-benzazepin-1-yl]acetic acid; 1H-1-Benzazepine-1-acetic acid, 3-(((1-(2-(ethoxycarbonyl)-4-phenylbutyl)cyclopentyl)carbonyl)amino)-2,3,4,5-tetrahydro-2-oxo-, (S-(R*,S*))-
    Click to Show/Hide
External Link
CID: 3038505
TTD: D01HDP
DrugBank: DB05796
 Compound Name Tonapofylline Phase 2 [15]
Synonyms
Bg 9928; 340021-17-2; BG-9928; UNII-83VNU4U44T; BG9928; CHEMBL386974; CHEMBL414157; 83VNU4U44T; 3-[4-(2,6-dioxo-1,3-dipropyl-7H-purin-8-yl)-1-bicyclo[222]octanyl]propanoic acid; bicyclo[222]octane-1-propanoic acid, 4-(2,3,6,9-tetrahydro-2,6-dioxo-1,3-dipropyl-1h-purin-8-yl)-; 3-[4-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo[222]oct-1-yl]-propionic acid; Bicyclo(222)octane-1-propanoic acid, 4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)-; Tonapofylline [USAN:INN]
    Click to Show/Hide
External Link
CID: 216466
TTD: D00SUK
DrugBank: DB12569
 Compound Name mRNA-0184 Phase 1 [16]
External Link
TTD: DKWS78
 Compound Name LY3461767 Phase 1 [17]
External Link
TTD: DJX7I5
 Compound Name JTT-861 Phase 1 [18]
External Link
TTD: D52MXY
 Compound Name ANX-042 Phase 1 [19]
Synonyms
BNP sliced variant (heart failure), Anexon; B-type natriuretic peptide spliced variant (heart failure), Anexon
    Click to Show/Hide
External Link
TTD: D0SZ5G
 Compound Name BMS-986224 Phase 1 [8]
External Link
TTD: D0IG7W
 Compound Name NOX-F37 Preclinical [15]
External Link
TTD: D09KAK
References
Ref 1 The lncRNA MIAT regulates CPT-1a mediated cardiac hypertrophy through m(6)A RNA methylation reading protein Ythdf2. Cell Death Discov. 2022 Apr 5;8(1):167. doi: 10.1038/s41420-022-00977-8.
Ref 2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6782).
Ref 3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6806).
Ref 5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4726).
Ref 6 ClinicalTrials.gov (NCT01214096) Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Subcutaneous Administration in Patients With Chronic Systolic Heart Failure. U.S. National Institutes of Health.
Ref 7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2199).
Ref 8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 9 ClinicalTrials.gov (NCT00810238) C-Cure Clinical Trial. U.S. National Institutes of Health.
Ref 10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5168).
Ref 11 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034446)
Ref 12 ClinicalTrials.gov (NCT02157506) A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure. U.S. National Institutes of Health.
Ref 13 ClinicalTrials.gov (NCT01096043) A Dose-Defining Study of CXL-1020 in Patients With Systolic Heart Failure. U.S. National Institutes of Health.
Ref 14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6506).
Ref 15 Emerging drugs for acute and chronic heart failure: current and future developments. Expert Opin Emerg Drugs. 2007 Mar;12(1):75-95.
Ref 16 ClinicalTrials.gov (NCT05659264) A Phase 1, Adaptive, Open-Label, Single Ascending Dose to Single-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-0184 in Participants With Chronic Heart Failure. U.S.National Institutes of Health.
Ref 17 ClinicalTrials.gov (NCT04840914) A Single-Dose Study Evaluating Different Dose Levels and Subcutaneous Infusion Durations on Safety, Pharmacokinetics, and Pharmacodynamics of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction. U.S.National Institutes of Health.
Ref 18 Clinical pipeline report, company report or official report of Akros Pharma
Ref 19 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800036485)